Soligenix CEO Highlights Rare Disease Therapeutics and Public Health Solutions Strategy
Soligenix's CEO discusses the company's two-pronged business model focused on rare disease treatments and public health solutions, emphasizing significant government funding and promising clinical trial developments.
Soligenix Inc., a late-stage biopharmaceutical company, is advancing multiple therapeutic programs across rare diseases and public health solutions, according to insights shared by CEO Dr. Christopher Schaber in a recent podcast interview.
The company's Specialized BioTherapeutics segment is developing HyBryte™, a novel photodynamic therapy for cutaneous T-cell lymphoma, following successful completion of its second Phase 3 study. Additional development programs include treatments for psoriasis, inflammatory diseases, and Behçet's Disease, utilizing innovative technologies like their first-in-class innate defense regulator platform.
In the Public Health Solutions segment, Soligenix has secured over $60 million in non-dilutive U.S. government funding. Key programs include RiVax®, a ricin toxin vaccine candidate, and vaccine developments targeting filoviruses like Marburg and Ebola, as well as COVID-19. These programs leverage the company's proprietary ThermoVax® heat stabilization platform technology.
The company is actively pursuing strategic opportunities, including potential partnerships and regulatory approvals for its advanced clinical pipeline. With a focus on addressing unmet medical needs in rare diseases and public health, Soligenix continues to position itself as an innovative biopharmaceutical developer with significant government and research support.